It is not too surprising to see cancer drugs well represented in the list of this year’s big launches given the R&D priorities of big pharma and biotech alike – three make the list, with Eli Lilly’s ramucirumab and Gilead Sciences’ idelalisib joining nivolumab.
A little more surprising, given the high cost and scale of clinical trials to get them to market, is the presence of four diabetes drugs, making treatments for endocrinerelated disorders the biggest category of products forecast for launch.(...)
Another category that tops the list, somewhat counterintuitively, is anti-infectives. A great deal of worry has been expressed about the future of antibiotics given the rise of resistance, and the industry has not been especially quick to respond. (Más)